TY - JOUR
T1 - An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas
AU - Yamamichi, Akane
AU - Kasama, Toshihiro
AU - Ohka, Fumiharu
AU - Suzuki, Hiromichi
AU - Kato, Akira
AU - Motomura, Kazuya
AU - Hirano, Masaki
AU - Ranjit, Melissa
AU - Chalise, Lushun
AU - Kurimoto, Michihiro
AU - Kondo, Goro
AU - Aoki, Kosuke
AU - Kaji, Noritada
AU - Tokeshi, Manabu
AU - Matsubara, Toshio
AU - Senga, Takeshi
AU - Kaneko, Mika K.
AU - Suzuki, Hidenori
AU - Hara, Masahito
AU - Wakabayashi, Toshihiko
AU - Baba, Yoshinobu
AU - Kato, Yukinari
AU - Natsume, Atsushi
N1 - Funding Information:
This work was supported by a JSPS KAKENHI [grant number 25462242]; Grant-in Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [grant number 23107010]; Practical Research for Innovation Cancer Control from Japan Agency for Medical Research and development, AMED; by ?Knowledge Hub Aichi?, Priority Research Project from Aichi Prefectural Government; by the Platform for Drug Discovery, Informatics, and Structural Life Science (PDIS) from AMED; and by the Regional Innovation Strategy Support Program from MEXT of Japan.
Publisher Copyright:
© 2016 The Author(s). Published by National Institute for Materials Science in partnership with Taylor & Francis.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.
AB - World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85019134989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019134989&partnerID=8YFLogxK
U2 - 10.1080/14686996.2016.1227222
DO - 10.1080/14686996.2016.1227222
M3 - Article
AN - SCOPUS:85019134989
VL - 17
SP - 618
EP - 625
JO - Science and Technology of Advanced Materials
JF - Science and Technology of Advanced Materials
SN - 1468-6996
IS - 1
ER -